Drug-eluting stents

A. Chieffo, A. Colombo

Research output: Contribution to journalArticle

Abstract

Drug-eluting stents represent the third revolution in the field of Interventional Cardiology following balloon angioplasty (PTCA) and the implantation of metal stents. The main limitation of percutaneous coronary intervention (PCI) is restenosis. The introduction of drug eluting stents able to release antiproliferative compounds led to the evaluation of several antiproliferative drugs in order to reduce restenosis. Rapamycin (Sirolimus) has been demonstrated to inhibit smooth muscle cell (SMC) proliferation and migration in vitro and to reduce in vivo neointima formation with blockage of the cell cycle progression at the G1-S transition. In a pilot study, recently confirmed by a randomized trial, rapamycin drug-eluting stents have been reported to eliminate restenosis after stent implantation. Promising data also come from the use of paclitaxel drug-eluting stents. Paclitaxel (Taxol) is a microtubule-stabilizing agent with potent antiproliferative activity. Even if drug-eluting stents represent one of the most promising fields in Interventional Cardiology today before being sure of their real potential it is necessary to wait for results from several ongoing clinical studies, their usage in real-world lesions and extended follow-up to 5 years.

Original languageEnglish
Pages (from-to)419-429
Number of pages11
JournalMinerva Cardioangiologica
Volume50
Issue number5
Publication statusPublished - Oct 2002

Fingerprint

Drug-Eluting Stents
Sirolimus
Paclitaxel
Cardiology
Stents
Neointima
Balloon Angioplasty
Excipients
Percutaneous Coronary Intervention
Microtubules
Smooth Muscle Myocytes
Cell Movement
Cell Cycle
Metals
Cell Proliferation
Pharmaceutical Preparations

Keywords

  • Coated materials, biocompatible
  • Graft occlusion, vascular, prevention and control
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chieffo, A., & Colombo, A. (2002). Drug-eluting stents. Minerva Cardioangiologica, 50(5), 419-429.

Drug-eluting stents. / Chieffo, A.; Colombo, A.

In: Minerva Cardioangiologica, Vol. 50, No. 5, 10.2002, p. 419-429.

Research output: Contribution to journalArticle

Chieffo, A & Colombo, A 2002, 'Drug-eluting stents', Minerva Cardioangiologica, vol. 50, no. 5, pp. 419-429.
Chieffo A, Colombo A. Drug-eluting stents. Minerva Cardioangiologica. 2002 Oct;50(5):419-429.
Chieffo, A. ; Colombo, A. / Drug-eluting stents. In: Minerva Cardioangiologica. 2002 ; Vol. 50, No. 5. pp. 419-429.
@article{ca1f14bbd44643658c19fe769c80eaaf,
title = "Drug-eluting stents",
abstract = "Drug-eluting stents represent the third revolution in the field of Interventional Cardiology following balloon angioplasty (PTCA) and the implantation of metal stents. The main limitation of percutaneous coronary intervention (PCI) is restenosis. The introduction of drug eluting stents able to release antiproliferative compounds led to the evaluation of several antiproliferative drugs in order to reduce restenosis. Rapamycin (Sirolimus) has been demonstrated to inhibit smooth muscle cell (SMC) proliferation and migration in vitro and to reduce in vivo neointima formation with blockage of the cell cycle progression at the G1-S transition. In a pilot study, recently confirmed by a randomized trial, rapamycin drug-eluting stents have been reported to eliminate restenosis after stent implantation. Promising data also come from the use of paclitaxel drug-eluting stents. Paclitaxel (Taxol) is a microtubule-stabilizing agent with potent antiproliferative activity. Even if drug-eluting stents represent one of the most promising fields in Interventional Cardiology today before being sure of their real potential it is necessary to wait for results from several ongoing clinical studies, their usage in real-world lesions and extended follow-up to 5 years.",
keywords = "Coated materials, biocompatible, Graft occlusion, vascular, prevention and control, Stents",
author = "A. Chieffo and A. Colombo",
year = "2002",
month = "10",
language = "English",
volume = "50",
pages = "419--429",
journal = "Minerva Cardioangiologica",
issn = "0026-4725",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Drug-eluting stents

AU - Chieffo, A.

AU - Colombo, A.

PY - 2002/10

Y1 - 2002/10

N2 - Drug-eluting stents represent the third revolution in the field of Interventional Cardiology following balloon angioplasty (PTCA) and the implantation of metal stents. The main limitation of percutaneous coronary intervention (PCI) is restenosis. The introduction of drug eluting stents able to release antiproliferative compounds led to the evaluation of several antiproliferative drugs in order to reduce restenosis. Rapamycin (Sirolimus) has been demonstrated to inhibit smooth muscle cell (SMC) proliferation and migration in vitro and to reduce in vivo neointima formation with blockage of the cell cycle progression at the G1-S transition. In a pilot study, recently confirmed by a randomized trial, rapamycin drug-eluting stents have been reported to eliminate restenosis after stent implantation. Promising data also come from the use of paclitaxel drug-eluting stents. Paclitaxel (Taxol) is a microtubule-stabilizing agent with potent antiproliferative activity. Even if drug-eluting stents represent one of the most promising fields in Interventional Cardiology today before being sure of their real potential it is necessary to wait for results from several ongoing clinical studies, their usage in real-world lesions and extended follow-up to 5 years.

AB - Drug-eluting stents represent the third revolution in the field of Interventional Cardiology following balloon angioplasty (PTCA) and the implantation of metal stents. The main limitation of percutaneous coronary intervention (PCI) is restenosis. The introduction of drug eluting stents able to release antiproliferative compounds led to the evaluation of several antiproliferative drugs in order to reduce restenosis. Rapamycin (Sirolimus) has been demonstrated to inhibit smooth muscle cell (SMC) proliferation and migration in vitro and to reduce in vivo neointima formation with blockage of the cell cycle progression at the G1-S transition. In a pilot study, recently confirmed by a randomized trial, rapamycin drug-eluting stents have been reported to eliminate restenosis after stent implantation. Promising data also come from the use of paclitaxel drug-eluting stents. Paclitaxel (Taxol) is a microtubule-stabilizing agent with potent antiproliferative activity. Even if drug-eluting stents represent one of the most promising fields in Interventional Cardiology today before being sure of their real potential it is necessary to wait for results from several ongoing clinical studies, their usage in real-world lesions and extended follow-up to 5 years.

KW - Coated materials, biocompatible

KW - Graft occlusion, vascular, prevention and control

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=0036808736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036808736&partnerID=8YFLogxK

M3 - Article

C2 - 12384624

AN - SCOPUS:0036808736

VL - 50

SP - 419

EP - 429

JO - Minerva Cardioangiologica

JF - Minerva Cardioangiologica

SN - 0026-4725

IS - 5

ER -